Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Vaginal Atrophy (Atrophic Vaginitis) Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) Overview | 7 | 1 |
| Vaginal Atrophy (Atrophic Vaginitis) Therapeutics under Development by Companies | 8 | 1 |
| Vaginal Atrophy (Atrophic Vaginitis) Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Vaginal Atrophy (Atrophic Vaginitis) Products under Development by Companies | 12 | 1 |
| Vaginal Atrophy (Atrophic Vaginitis) Companies Involved in Therapeutics Development | 13 | 6 |
| Allergan Plc | 13 | 1 |
| EndoCeutics, Inc. | 14 | 1 |
| Foamix Pharmaceuticals Ltd. | 15 | 1 |
| Ligand Pharmaceuticals, Inc. | 16 | 1 |
| Mithra Pharmaceuticals S.A. | 17 | 1 |
| PEPTONIC medical AB | 18 | 1 |
| Vaginal Atrophy (Atrophic Vaginitis) Therapeutics Assessment | 19 | 9 |
| Assessment by Monotherapy Products | 19 | 1 |
| Assessment by Target | 20 | 2 |
| Assessment by Mechanism of Action | 22 | 2 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 13 |
| Estetrol Drug Profile | 28 | 3 |
| estradiol hemihydrate Drug Profile | 31 | 1 |
| lasofoxifene tartrate Drug Profile | 32 | 3 |
| oxytocin Drug Profile | 35 | 2 |
| prasterone Drug Profile | 37 | 2 |
| WC-3011 Drug Profile | 39 | 2 |
| Vaginal Atrophy (Atrophic Vaginitis) Dormant Projects | 41 | 1 |
| Vaginal Atrophy (Atrophic Vaginitis) Product Development Milestones | 42 | 9 |
| Featured News &Press Releases | 42 | 1 |
| May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor | 42 | 1 |
| Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study | 42 | 1 |
| Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting | 43 | 1 |
| Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause | 44 | 1 |
| Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting | 45 | 1 |
| Jul 17, 2015: Last subject exits Peptonic Medical s phase 2b VVA study | 46 | 1 |
| Mar 30, 2015: Vulvovaginal atrophy symptoms improve with prasterone treatment | 46 | 1 |
| Mar 23, 2015: Peptonic Medical s formulation patent to be approved in the USA | 47 | 1 |
| Mar 18, 2015: Patient recruitment to Peptonic Medical s phase 2b study soon completed | 47 | 1 |
| Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin | 48 | 1 |
| Dec 01, 2014: Peptonic Medical s formulation patent to be approved in Europe | 48 | 1 |
| Oct 28, 2014: First patients included in Peptonic Medical AB s clinical phase 2b study | 48 | 1 |
| Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study | 49 | 1 |
| Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study | 49 | 1 |
| Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden | 50 | 1 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |